Powder: -20°C for 3 years | In solvent: -80°C for 2 years
Heparin sodium salt 是一种抗凝剂,可与抗凝血酶 III 可逆地结合,使凝血酶因子 IIa 和 Xa 的失活速度加快,显着抑制外泌体-细胞相互作用。
产品描述 | Heparin sodium is a sulfated polysaccharide, which belongs to the family of glycosaminoglycans. It is utilized as an anticoagulant and interacted with diverse proteins for numerous important biological activities.Heparin sodium salt significantly inhibits exosome-cell interactions. |
体外活性 | Heparin contains a speci?c pentasaccharide sequence that binds and activates the plasma proteinase inhibitor AT, which accounts for most of the increase in inhibitory activity toward Factor Xa induced by heparin. Heparin binds, via the speci?c pentasaccharide sequence, to AT is a two-step process, involving formation of an initial complex with a Kd of ~4×10?5M, followed by conformational changes in both the AT and saccharide moieties. Heparin 12-mer binds to FGF2 monomer covalently is able to induce FGFR activation (stimulate mitogenesis). [1] Heparin induces aggregation of platelets in citrated platelet-rich plasma and enhances platelet aggregation and serotonin secretion induced by other agents, and this action of heparin is blocked by substances that elevate platelet cyclic AMP and by EDTA but not by inhibitors of platelet cyclooxygenase. [2] Heparin controls, through a post-translational mechanism, the levels of specific cassettes of positively charged proteases inside mast cells. [3] Heparin activates the inhibition of thrombin by antithrombin by bringing them into close apposition, but there is also a direct activation of inhibition due to an overall conformational change induced by the binding to the core pentasaccharide present in both heparin and heparans. [4] |
激酶实验 | In vitro assay of CYP17: The in vitro CYP17 inhibitory activity of Galeterone is evaluated using rapid acetic acid releasing assay (AARA), utilizing intact P450c17-expressing E. coli as the enzyme source. It involves the use of [21-3H]-17α-hydroxypregnenolone as the substrate, and CYP17 activity is measured by the amount of tritiated acetic acid formed during the cleavage of the C-21 side chain of the substrate. IC50 value is obtained directly from plots relating percentage inhibition versus inhibitor concentration over appropriate ranges. |
别名 | 肝素钠, Heparin sodium, Sodium heparinate |
化合物与蛋白结合的复合物 |
Crystal structure of heparin lyase I complexed with disaccharide heparin |
分子量 | 1157.89 |
分子式 | C26H42N2NaO37S5 |
CAS No. | 9041-08-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 2 years
H2O: 20 mg/mL, Need ultrasonic
( < 1 mg/mL refers to the product slightly soluble or insoluble )
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
bottom
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Heparin sodium salt 9041-08-1 Autophagy Metabolism Proteases/Proteasome Thrombin Factor Xa 肝素钠 Heparin sodium Sodium heparinate Inhibitor inhibitor inhibit